TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study

G Rindi; M Falconi; C Klersy; L Albarello; L Boninsegna; MW Buchler; C Capella; M Caplin; A Couvelard; C Doglioni; G delle Fave; L Fischer; G Fusai; W.W. de Herder; H Jann; P Komminoth; Ronald de Krijger; S La Rosa; TV Luong; U Pape; A Perren; P Ruszniewski; A Scarpa; A Schmitt; E Solcia; B Wiedenmann

doi:10.1093/jnci/djs208

TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study

G Rindi, M Falconi, C Klersy, L Albarello, L Boninsegna, MW Buchler, C Capella, M Caplin, A Couvelard, C Doglioni, G delle Fave, L Fischer, G Fusai, W.W. de Herder, H Jann, P Komminoth, Ronald de Krijger, S La Rosa, TV Luong, U PapeA Perren, P Ruszniewski, A Scarpa, A Schmitt, E Solcia, B Wiedenmann

Research output: Contribution to journal › Article › Academic › peer-review

377 Citations (Scopus)

Abstract

Background Both the European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/American Joint Cancer Committee/World Health Organization (UICC/AJCC/WHO) have proposed TNM staging systems for pancreatic neuroendocrine neoplasms. This study aims to identify the most accurate and useful TNM system for pancreatic neuroendocrine neoplasms. Methods The study included 1072 patients who had undergone previous surgery for their cancer and for which at least 2 years of follow-up from 1990 to 2007 was available. Data on 28 variables were collected, and the performance of the two TNM staging systems was compared by Cox regression analysis and multivariable analyses. All statistical tests were two-sided. Results Differences in distribution of sex and age were observed for the ENETS TNM staging system. At Cox regression analysis, only the ENETS TNM staging system perfectly allocated patients into four statistically significantly different and equally populated risk groups (with stage I as the reference; stage II hazard ratio [HR] of death = 16.23, 95% confidence interval [CI] = 2.14 to 123, P = .007; stage III HR of death = 51.81, 95% CI = 7.11 to 377, P < .001; and stage IV HR of death = 160, 95 Conclusion Our data suggest the ENETS TNM staging system is superior to the UICC/AJCC/WHO 2010 TNM staging system and supports its use in clinical practice.

Original language	Undefined/Unknown
Pages (from-to)	764-777
Number of pages	14
Journal	Journal of the National Cancer Institute
Volume	104
Issue number	10
DOIs	https://doi.org/10.1093/jnci/djs208
Publication status	Published - 2012

Research programs

EMC MM-01-39-01
EMC MM-03-24-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/djs208

http://hdl.handle.net/1765/56758

Cite this

Rindi, G., Falconi, M., Klersy, C., Albarello, L., Boninsegna, L., Buchler, MW., Capella, C., Caplin, M., Couvelard, A., Doglioni, C., delle Fave, G., Fischer, L., Fusai, G., de Herder, W. W., Jann, H., Komminoth, P., de Krijger, R., La Rosa, S., Luong, TV., ... Wiedenmann, B. (2012). TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study. Journal of the National Cancer Institute, 104(10), 764-777. https://doi.org/10.1093/jnci/djs208

@article{f1c1f19b840e43aeb8ceab13fddd3bee,

title = "TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study",

abstract = "Background Both the European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/American Joint Cancer Committee/World Health Organization (UICC/AJCC/WHO) have proposed TNM staging systems for pancreatic neuroendocrine neoplasms. This study aims to identify the most accurate and useful TNM system for pancreatic neuroendocrine neoplasms. Methods The study included 1072 patients who had undergone previous surgery for their cancer and for which at least 2 years of follow-up from 1990 to 2007 was available. Data on 28 variables were collected, and the performance of the two TNM staging systems was compared by Cox regression analysis and multivariable analyses. All statistical tests were two-sided. Results Differences in distribution of sex and age were observed for the ENETS TNM staging system. At Cox regression analysis, only the ENETS TNM staging system perfectly allocated patients into four statistically significantly different and equally populated risk groups (with stage I as the reference; stage II hazard ratio [HR] of death = 16.23, 95% confidence interval [CI] = 2.14 to 123, P = .007; stage III HR of death = 51.81, 95% CI = 7.11 to 377, P < .001; and stage IV HR of death = 160, 95 Conclusion Our data suggest the ENETS TNM staging system is superior to the UICC/AJCC/WHO 2010 TNM staging system and supports its use in clinical practice.",

author = "G Rindi and M Falconi and C Klersy and L Albarello and L Boninsegna and MW Buchler and C Capella and M Caplin and A Couvelard and C Doglioni and {delle Fave}, G and L Fischer and G Fusai and {de Herder}, W.W. and H Jann and P Komminoth and {de Krijger}, Ronald and {La Rosa}, S and TV Luong and U Pape and A Perren and P Ruszniewski and A Scarpa and A Schmitt and E Solcia and B Wiedenmann",

year = "2012",

doi = "10.1093/jnci/djs208",

language = "Undefined/Unknown",

volume = "104",

pages = "764--777",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "10",

}

Rindi, G, Falconi, M, Klersy, C, Albarello, L, Boninsegna, L, Buchler, MW, Capella, C, Caplin, M, Couvelard, A, Doglioni, C, delle Fave, G, Fischer, L, Fusai, G, de Herder, WW, Jann, H, Komminoth, P, de Krijger, R, La Rosa, S, Luong, TV, Pape, U, Perren, A, Ruszniewski, P, Scarpa, A, Schmitt, A, Solcia, E & Wiedenmann, B 2012, 'TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study', Journal of the National Cancer Institute, vol. 104, no. 10, pp. 764-777. https://doi.org/10.1093/jnci/djs208

TY - JOUR

T1 - TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study

AU - Rindi, G

AU - Falconi, M

AU - Klersy, C

AU - Albarello, L

AU - Boninsegna, L

AU - Buchler, MW

AU - Capella, C

AU - Caplin, M

AU - Couvelard, A

AU - Doglioni, C

AU - delle Fave, G

AU - Fischer, L

AU - Fusai, G

AU - de Herder, W.W.

AU - Jann, H

AU - Komminoth, P

AU - de Krijger, Ronald

AU - La Rosa, S

AU - Luong, TV

AU - Pape, U

AU - Perren, A

AU - Ruszniewski, P

AU - Scarpa, A

AU - Schmitt, A

AU - Solcia, E

AU - Wiedenmann, B

PY - 2012

Y1 - 2012

N2 - Background Both the European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/American Joint Cancer Committee/World Health Organization (UICC/AJCC/WHO) have proposed TNM staging systems for pancreatic neuroendocrine neoplasms. This study aims to identify the most accurate and useful TNM system for pancreatic neuroendocrine neoplasms. Methods The study included 1072 patients who had undergone previous surgery for their cancer and for which at least 2 years of follow-up from 1990 to 2007 was available. Data on 28 variables were collected, and the performance of the two TNM staging systems was compared by Cox regression analysis and multivariable analyses. All statistical tests were two-sided. Results Differences in distribution of sex and age were observed for the ENETS TNM staging system. At Cox regression analysis, only the ENETS TNM staging system perfectly allocated patients into four statistically significantly different and equally populated risk groups (with stage I as the reference; stage II hazard ratio [HR] of death = 16.23, 95% confidence interval [CI] = 2.14 to 123, P = .007; stage III HR of death = 51.81, 95% CI = 7.11 to 377, P < .001; and stage IV HR of death = 160, 95 Conclusion Our data suggest the ENETS TNM staging system is superior to the UICC/AJCC/WHO 2010 TNM staging system and supports its use in clinical practice.

AB - Background Both the European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/American Joint Cancer Committee/World Health Organization (UICC/AJCC/WHO) have proposed TNM staging systems for pancreatic neuroendocrine neoplasms. This study aims to identify the most accurate and useful TNM system for pancreatic neuroendocrine neoplasms. Methods The study included 1072 patients who had undergone previous surgery for their cancer and for which at least 2 years of follow-up from 1990 to 2007 was available. Data on 28 variables were collected, and the performance of the two TNM staging systems was compared by Cox regression analysis and multivariable analyses. All statistical tests were two-sided. Results Differences in distribution of sex and age were observed for the ENETS TNM staging system. At Cox regression analysis, only the ENETS TNM staging system perfectly allocated patients into four statistically significantly different and equally populated risk groups (with stage I as the reference; stage II hazard ratio [HR] of death = 16.23, 95% confidence interval [CI] = 2.14 to 123, P = .007; stage III HR of death = 51.81, 95% CI = 7.11 to 377, P < .001; and stage IV HR of death = 160, 95 Conclusion Our data suggest the ENETS TNM staging system is superior to the UICC/AJCC/WHO 2010 TNM staging system and supports its use in clinical practice.

U2 - 10.1093/jnci/djs208

DO - 10.1093/jnci/djs208

M3 - Article

C2 - 22525418

SN - 0027-8874

VL - 104

SP - 764

EP - 777

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 10

ER -